ACADIA Pharma Executive Compensation Details Revealed
Ticker: ACAD · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1070494
| Field | Detail |
|---|---|
| Company | Acadia Pharmaceuticals Inc (ACAD) |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, governance
Related Tickers: ACAD
TL;DR
ACADIA Pharma's 2025 DEF 14A drops: exec comp details for 2024 are in, equity awards for Davis & Adams highlighted.
AI Summary
ACADIA Pharmaceuticals Inc. filed its DEF 14A on April 25, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to key executives like Stephen R. Davis and Catherine Owen Adams, with details on their fair value and vesting conditions.
Why It Matters
This filing provides transparency into how ACADIA Pharmaceuticals compensates its top executives, which can influence investor perception and corporate governance.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing detailing executive compensation and does not present new financial risks.
Key Players & Entities
- ACADIA Pharmaceuticals Inc. (company) — Filer
- Stephen R. Davis (person) — Executive
- Catherine Owen Adams (person) — Executive
- 2024-12-31 (date) — Fiscal Year End
- 20250425 (date) — Filing Date
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose of this DEF 14A filing is to provide detailed information regarding ACADIA Pharmaceuticals Inc.'s executive compensation, director compensation, and other corporate governance matters for the fiscal year ending December 31, 2024.
Who are the named executive officers whose compensation is detailed in this filing?
The filing details compensation for named executive officers, including Stephen R. Davis and Catherine Owen Adams, among others, for the fiscal year 2024.
What types of equity awards are discussed for the executives?
The filing discusses various equity awards, including changes in fair value of equity awards, equity awards granted, and outstanding unvested equity awards, for the fiscal year 2024.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 25, 2025.
What is the fiscal year end for ACADIA Pharmaceuticals Inc. as stated in the filing?
The fiscal year end for ACADIA Pharmaceuticals Inc. is December 31.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 by Stephen R. Davis regarding ACADIA PHARMACEUTICALS INC (ACAD).